1. Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis.
- Author
-
Vugler A, O'connell J, Nguyen MA, Weitz D, Leeuw T, Hickford E, Verbitsky A, Ying X, Rehberg M, Carrington B, Merriman M, Moss A, Nicolas JM, Stanley P, Wright S, Bourne T, Foricher Y, Zhu Z, Brookings D, Horsley H, Heer J, Schio L, Herrmann M, Rao S, Kohlmann M, and Florian P
- Abstract
[This corrects the article DOI: 10.3389/fphar.2022.1037983.]., Competing Interests: AV, JO'C, MN, DW, TL, EH, AVe, XY, MR, BC, MM, AM, J-MN, PS, SW, YF, ZZ, DB, HH, JH, LS, MH, SR, MK, and PF are either employees of UCB Pharma or Sanofi and may hold stock of the respective organizations. PF was employed by Sanofi-Aventis Deutschland GmbH at the time the work of the manuscript was conducted. He is now an employee of Boehringer Ingelheim Vetmedica GmbH. TB was employed by Milvuswood Consultancy. The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated., (Copyright © 2024 Vugler, O’connell, Nguyen, Weitz, Leeuw, Hickford, Verbitsky, Ying, Rehberg, Carrington, Merriman, Moss, Nicolas, Stanley, Wright, Bourne, Foricher, Zhu, Brookings, Horsley, Heer, Schio, Herrmann, Rao, Kohlmann and Florian.)
- Published
- 2024
- Full Text
- View/download PDF